Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 348 shares, a drop of 76.4% from the July 15th total of 1,472 shares. Based on an average daily trading volume, of 1,908 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Daxor Price Performance

Shares of NASDAQ:DXR traded up $0.25 during trading on Thursday, reaching $10.45. 527 shares of the company’s stock traded hands, compared to its average volume of 7,061. Daxor has a 12 month low of $8.56 and a 12 month high of $14.76. The company has a 50 day moving average of $10.36 and a 200-day moving average of $10.76.

Hedge Funds Weigh In On Daxor

Several institutional investors have recently made changes to their positions in DXR. Osaic Holdings Inc. acquired a new stake in shares of Daxor during the 2nd quarter worth approximately $86,000. Crescent Grove Advisors LLC acquired a new position in Daxor during the 1st quarter valued at approximately $104,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Daxor during the 4th quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Daxor during the 1st quarter worth $245,000. Finally, Aristides Capital LLC bought a new position in Daxor during the 1st quarter worth $403,000. 1.34% of the stock is owned by institutional investors.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.